DrugMapper
Browse
Therapeutic Area
CANCER (51)
CARDIOVASCULAR (45)
DENTISTRY (2)
DERMATOLOGY (31)
DIABETES DRUGS & ENDOCRINOLOGY (61)
EMERGENCY MEDICINE (3)
ENT (5)
EYE (23)
GASTROINTESTINAL (29)
HEMATOLOGY (23)
MUSCULOSKELETAL (28)
NEUROLOGY DRUGS & NERVOUS SYSTEM (50)
PEDIATRICS (27)
PHARMACOLOGY (8)
PREGNANCY AND GYNECOLOGY (30)
RESPIRATORY (42)
RHEUMATOLOGY (19)
OTHER (1482)
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Primary Target
Target Level
Level 1
Level 2
Level 3
Level 4
Level 5
Level 6
Active Pharmaceutical Ingredients (APIs)
Small Molecules
ProDrugs
Antibodies
CNS drugs
Metabolites
Search
Therapeutic Indication
Adverse Reaction (System Organ Classification)
Mechanism of Action
Target Sequence
Chemical Structure
Physicochemical Properties
Analyze
Networks
Chemical Similarity
Scaffold Similarity
KNIME workflow
Downloads
Web services
Bulk Downloads
About
DrugMapper FAQs
Data Sources
Contact Us
Display Options:
Drug type
Therapeutic Area
Route of administration
Mechanism of Action
Indication
Status
Total:
6532
TC-6987
2
Small molecule
Investigational
Unknown
Unknown
Asthma; Diabetes Mellitus, Type 2
Neuronal acetylcholine receptor protein alpha-7 subunit agonist
TC-6987
×
Maximum Phase:
2
First Approval:
None
UNII:
Q2U4R164OG
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
STX107
2
Small molecule
Investigational
Unknown
Unknown
Fragile X Syndrome
Metabotropic glutamate receptor 5 negative allosteric modulator
STX107
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
LY2590443
2
Small molecule
Investigational
Unknown
Unknown
Migraine Disorders
Serotonin 7 (5-HT7) receptor antagonist
LY2590443
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
ITRIGLUMIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Cholecystokinin B receptor antagonist
ITRIGLUMIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
879A12466H
Molecule Type:
Small molecule
Molecular Formula:
C33H38N2O4
Molecular Weight:
526.68
AlogP:
6.84
PSA:
86.71
HBD:
2.0
HBA:
#RotB:
7.0
Source:
ACLARUBICIN
2
Small molecule
Investigational
Unknown
Unknown
Myelodysplastic Syndromes; Leukemia, Myeloid, Acute; Neoplasms
Unknown
ACLARUBICIN
×
Maximum Phase:
2
First Approval:
None
UNII:
74KXF8I502
Molecule Type:
Small molecule
Molecular Formula:
C42H53NO15
Molecular Weight:
811.88
AlogP:
3.16
PSA:
217.05
HBD:
4.0
HBA:
#RotB:
9.0
Source:
VODOBATINIB
2
Small molecule
Investigational
Unknown
Unknown
Leukemia, Myelogenous, Chronic, BCR-ABL Positive; Dementia; Parkinson Disease
Bcr/Abl fusion protein inhibitor
VODOBATINIB
×
Maximum Phase:
2
First Approval:
None
UNII:
N8Q12KU2SW
Molecule Type:
Small molecule
Molecular Formula:
C27H20ClN3O2
Molecular Weight:
453.93
AlogP:
4.98
PSA:
71.09
HBD:
2.0
HBA:
#RotB:
2.0
Source:
ONC201
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
ONC201
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
PF-05212377
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease
Serotonin 6 (5-HT6) receptor antagonist
PF-05212377
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TOPIROXOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Nephropathies; Hyperuricemia
Xanthine dehydrogenase inhibitor
TOPIROXOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
0J877412JV
Molecule Type:
Small molecule
Molecular Formula:
C13H8N6
Molecular Weight:
248.25
AlogP:
1.8
PSA:
91.14
HBD:
1.0
HBA:
#RotB:
2.0
Source:
PF-00446687
2
Small molecule
Investigational
Unknown
Unknown
Erectile Dysfunction; Sexual Dysfunction, Physiological
Melanocortin receptor 4 agonist
PF-00446687
×
Maximum Phase:
2
First Approval:
None
UNII:
63P236Z73I
Molecule Type:
Small molecule
Molecular Formula:
C28H36F2N2O2
Molecular Weight:
470.6
AlogP:
4.78
PSA:
43.78
HBD:
1.0
HBA:
#RotB:
3.0
Source:
DELPARANTAG
2
Small molecule
Investigational
Unknown
Unknown
Coronary Disease
Unknown
DELPARANTAG
×
Maximum Phase:
2
First Approval:
None
UNII:
FSY46235ZO
Molecule Type:
Small molecule
Molecular Formula:
C56H79N13O12
Molecular Weight:
1126.33
AlogP:
None
PSA:
None
HBD:
None
HBA:
#RotB:
None
Source:
SETOGEPRAM
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
SETOGEPRAM
×
Maximum Phase:
2
First Approval:
None
UNII:
879OVM0Y1S
Molecule Type:
Small molecule
Molecular Formula:
C13H18O2
Molecular Weight:
206.28
AlogP:
3.05
PSA:
37.3
HBD:
1.0
HBA:
#RotB:
6.0
Source:
BISOCTRIZOLE
2
Small molecule
Investigational
Unknown
Unknown
Urticaria
Sunscreen
BISOCTRIZOLE
×
Maximum Phase:
2
First Approval:
None
UNII:
8NT850T0YS
Molecule Type:
Small molecule
Molecular Formula:
C41H50N6O2
Molecular Weight:
658.89
AlogP:
9.58
PSA:
101.88
HBD:
2.0
HBA:
#RotB:
8.0
Source:
NAVOCAFTOR
2
Small molecule
Investigational
Unknown
Unknown
Cystic Fibrosis
Unknown
NAVOCAFTOR
×
Maximum Phase:
2
First Approval:
None
UNII:
W2F2XU189O
Molecule Type:
Small molecule
Molecular Formula:
C15H11F3N4O5S
Molecular Weight:
416.34
AlogP:
1.94
PSA:
141.43
HBD:
2.0
HBA:
#RotB:
5.0
Source:
TOSEDOSTAT
2
Small molecule
Investigational
Unknown
Unknown
Carcinoma, Non-Small-Cell Lung; Neoplasms; Pancreatic Neoplasms; Leukemia, Myeloid, Acute; Myelodysplastic Syndromes
Aminopeptidase inhibitor
TOSEDOSTAT
×
Maximum Phase:
2
First Approval:
None
UNII:
KZK563J2UW
Molecule Type:
Small molecule
Molecular Formula:
C21H30N2O6
Molecular Weight:
406.48
AlogP:
1.86
PSA:
124.96
HBD:
4.0
HBA:
#RotB:
9.0
Source:
BAVISANT DIHYDROCHLORIDE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
BAVISANT DIHYDROCHLORIDE
×
Maximum Phase:
2
First Approval:
None
UNII:
C1H7H5X3RE
Molecule Type:
Small molecule
Molecular Formula:
C19H31Cl2N3O3
Molecular Weight:
420.38
AlogP:
1.44
PSA:
36.02
HBD:
0.0
HBA:
#RotB:
4.0
Source:
ADL-5747
2
Small molecule
Investigational
Unknown
Unknown
Neuralgia, Postherpetic; Osteoarthritis, Knee
Delta opioid receptor agonist
ADL-5747
×
Maximum Phase:
2
First Approval:
None
UNII:
BRJ718SA03
Molecule Type:
Small molecule
Molecular Formula:
C24H29ClN2O3
Molecular Weight:
428.96
AlogP:
3.82
PSA:
61.8
HBD:
2.0
HBA:
#RotB:
4.0
Source:
YM598
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
YM598
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
IMD-1041
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Inhibitor of nuclear factor kappa B kinase beta subunit inhibitor
IMD-1041
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TK-112690
2
Small molecule
Investigational
Unknown
Unknown
Mucositis
Unknown
TK-112690
×
Maximum Phase:
2
First Approval:
None
UNII:
GQZ99GWR3T
Molecule Type:
Small molecule
Molecular Formula:
C10H12N2O5
Molecular Weight:
240.22
AlogP:
-1.44
PSA:
93.81
HBD:
2.0
HBA:
#RotB:
1.0
Source:
TEPILAMIDE FUMARATE
2
Small molecule
Investigational
Unknown
Unknown
Psoriasis
Unknown
TEPILAMIDE FUMARATE
×
Maximum Phase:
2
First Approval:
None
UNII:
KOS9TZ09CM
Molecule Type:
Small molecule
Molecular Formula:
C11H17NO5
Molecular Weight:
243.26
AlogP:
0.13
PSA:
72.91
HBD:
0.0
HBA:
#RotB:
6.0
Source:
TRIACETIN
2
Small molecule
Investigational
Unknown
Unknown
Canavan Disease
Unknown
TRIACETIN
×
Maximum Phase:
2
First Approval:
None
UNII:
XHX3C3X673
Molecule Type:
Small molecule
Molecular Formula:
C9H14O6
Molecular Weight:
218.21
AlogP:
0.04
PSA:
78.9
HBD:
0.0
HBA:
#RotB:
5.0
Source:
CB-103
2
Small molecule
Investigational
Unknown
Unknown
Breast Neoplasms
Unknown
CB-103
×
Maximum Phase:
2
First Approval:
None
UNII:
Q5BB91JL0V
Molecule Type:
Small molecule
Molecular Formula:
C15H18N2O
Molecular Weight:
242.32
AlogP:
3.75
PSA:
48.14
HBD:
1.0
HBA:
#RotB:
2.0
Source:
FLUBROBENGUANE
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
FLUBROBENGUANE
×
Maximum Phase:
2
First Approval:
None
UNII:
XCG95AYX3B
Molecule Type:
Small molecule
Molecular Formula:
C11H15BrFN3O
Molecular Weight:
304.16
AlogP:
2.17
PSA:
71.13
HBD:
3.0
HBA:
#RotB:
6.0
Source:
AEE-788
2
Small molecule
Investigational
Unknown
Unknown
Central Nervous System Neoplasms; Glioblastoma; Neoplasms
Epidermal growth factor receptor erbB1 inhibitor
AEE-788
×
Maximum Phase:
2
First Approval:
None
UNII:
F9JLR95I3I
Molecule Type:
Small molecule
Molecular Formula:
C27H32N6
Molecular Weight:
440.6
AlogP:
4.94
PSA:
60.08
HBD:
2.0
HBA:
#RotB:
7.0
Source:
NAVAFENTEROL
2
Small molecule
Investigational
Unknown
Unknown
Pulmonary Disease, Chronic Obstructive
Beta-2 adrenergic receptor agonist
NAVAFENTEROL
×
Maximum Phase:
2
First Approval:
None
UNII:
U29GY32XJ4
Molecule Type:
Small molecule
Molecular Formula:
C38H42N6O6S2
Molecular Weight:
742.92
AlogP:
5.04
PSA:
165.83
HBD:
5.0
HBA:
#RotB:
14.0
Source:
CARBAPENEM
2
Small molecule
Investigational
Unknown
Unknown
Infections
Unknown
CARBAPENEM
×
Maximum Phase:
2
First Approval:
None
UNII:
GL970841YS
Molecule Type:
Small molecule
Molecular Formula:
C7H7NO3
Molecular Weight:
153.14
AlogP:
-0.04
PSA:
57.61
HBD:
1.0
HBA:
#RotB:
1.0
Source:
ADENOSINE TRIPHOSPHATE
2
Small molecule
Investigational
Unknown
Unknown
Alzheimer Disease; Depressive Disorder, Major
Unknown
ADENOSINE TRIPHOSPHATE
×
Maximum Phase:
2
First Approval:
None
UNII:
8L70Q75FXE
Molecule Type:
Small molecule
Molecular Formula:
C10H16N5O13P3
Molecular Weight:
507.18
AlogP:
-1.63
PSA:
279.13
HBD:
7.0
HBA:
#RotB:
8.0
Source:
LY2157299
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Unknown
LY2157299
×
Maximum Phase:
2
First Approval:
None
UNII:
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
TG100-801
2
Small molecule
Investigational
Unknown
Unknown
Diabetic Retinopathy; Macular Degeneration; Wet Macular Degeneration
Ephrin type-B receptor 4 inhibitor
TG100-801
×
Maximum Phase:
2
First Approval:
None
UNII:
1VZO7A0J9S
Molecule Type:
Small molecule
Molecular Formula:
C33H30ClN5O3
Molecular Weight:
580.09
AlogP:
7.09
PSA:
89.47
HBD:
1.0
HBA:
#RotB:
9.0
Source:
4-IMIDAZOLECARBOXYLIC ACID
2
Small molecule
Investigational
Unknown
Unknown
Dermatitis, Atopic
Unknown
4-IMIDAZOLECARBOXYLIC ACID
×
Maximum Phase:
2
First Approval:
None
UNII:
AE82Z8U4GJ
Molecule Type:
Small molecule
Molecular Formula:
C4H4N2O2
Molecular Weight:
112.09
AlogP:
0.11
PSA:
65.98
HBD:
2.0
HBA:
#RotB:
1.0
Source:
TAK-653
2
Small molecule
Investigational
Unknown
Unknown
Depressive Disorder
Glutamate receptor ionotropic AMPA positive allosteric modulator
TAK-653
×
Maximum Phase:
2
First Approval:
None
UNII:
9E3TOE5RIZ
Molecule Type:
Small molecule
Molecular Formula:
C19H23N3O3S
Molecular Weight:
373.48
AlogP:
3.11
PSA:
71.33
HBD:
0.0
HBA:
#RotB:
3.0
Source:
PHOSPHORYLETHANOLAMINE
2
Small molecule
Investigational
Unknown
Unknown
Neoplasms
Unknown
PHOSPHORYLETHANOLAMINE
×
Maximum Phase:
2
First Approval:
None
UNII:
78A2BX7AEU
Molecule Type:
Small molecule
Molecular Formula:
C2H8NO4P
Molecular Weight:
141.06
AlogP:
-0.95
PSA:
92.78
HBD:
3.0
HBA:
#RotB:
3.0
Source:
BL-1020
2
Small molecule
Investigational
Unknown
Unknown
Psychotic Disorders; Schizophrenia
Unknown
BL-1020
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
C25H34Cl2N4O2S
Molecular Weight:
525.55
AlogP:
4.23
PSA:
62.04
HBD:
1.0
HBA:
#RotB:
10.0
Source:
S-237648
2
Small molecule
Investigational
Unknown
Unknown
Unknown
Neuropeptide Y receptor type 5 antagonist
S-237648
×
Maximum Phase:
2
First Approval:
None
UNII:
None
Molecule Type:
Small molecule
Molecular Formula:
Molecular Weight:
AlogP:
PSA:
HBD:
HBA:
#RotB:
Source:
1
2
…
91
92
93
94
95
96
97
…
186
187
Next »
Download Option
Close
Header
Compound Name
Maximum Phase
Compound Structure
Smile
Inchi
InchiKey
Compound Properties
Molecular Formula
Molecular Weight
ALogP
PSA